The prognostic impact of immune-related adverse events during anti-PD1 treatment in melanoma and non–small-cell lung cancer: a real-life retrospective study

Background: Nivolumab and pembrolizumab, two PD1 inhibitors, trigger immune-related adverse events in approximately 50% of patients. Our objective was to determine whether these immune-related adverse events are associated with patient outcomes. Patients and Methods: Retrospective cohort study, real...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupont, R., Bérard, E., Puisset, F., Comont, T., Delord, J.-P., Guimbaud, R., Meyer, N., Mazieres, J., Alric, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959447/
https://www.ncbi.nlm.nih.gov/pubmed/32002292
http://dx.doi.org/10.1080/2162402X.2019.1682383

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6959447/
https://www.ncbi.nlm.nih.gov/pubmed/32002292
http://dx.doi.org/10.1080/2162402X.2019.1682383

Ejemplares similares